ledipasvir/sofosbuvir / Generic mfg. - LARVOL DELTA

Hepatitis C Treatment During Pregnancy: Time for a Practice Change. (PubMed, Am J Obstet Gynecol MFM) - "Ledipasvir/sofosbuvir and sofosbuvir/velpatasvir currently have the most data available in pregnancy and should be included in conversations regarding HCV treatment in pregnancy. Multidisciplinary care between maternal-fetal medicine, infectious disease, and hepatology can help promote access to HCV treatment in pregnancy."

Journal • Review • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Obstetrics

Consideration of ledipasvir/sofosbuvir as an alternative to glecaprevir/pibrentasvir based upon on-treatment FIB-4 changes and sustained virologic response at 12 weeks in hepatitis C genotype 1 and 2 infections: A propensity score-matched study. (PubMed, Medicine (Baltimore)) - "Fixed doses of LDV/SOF and GLE/PIB are effective for treating HCV GT-1 and GT-2 infections. There were no significant differences between the 2 regimens in on-treatment FIB-4 changes upon reaching SVR 12."

Clinical • Journal • Observational data • Retrospective data • Fibrosis • Hepatitis C • Immunology • Infectious Disease • Inflammation

Paraneoplastic Minimal Change Disease Revealing an Underlying High-Grade Neuroendocrine Carcinoma: A Case Report (KIDNEY WEEK 2025) - "Case Description A 68-year-old male with HIV in remission, Hepatitis C treated with Harvoni, hyperlipidemia, CAD, and CKD presented with hypertensive urgency and AKI...Urine toxicology was positive for cocaine, methadone, and opiates...Recognizing this distinction is crucial to its therapeutic implications: remission of nephrotic syndrome has been observed following successful treatment of the underlying condition. In this case, nephrotic syndrome with abnormal MLN and remission of HIV and hepatitis B raised concern for malignancy, prompting a lung mass biopsy that confirmed the diagnosis."

Case report • Clinical • Chronic Kidney Disease • Dyslipidemia • Endocrine Cancer • Glomerulonephritis • Hematological Malignancies • Hepatitis B • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Lymphoma • Nephrology • Neuroendocrine Carcinoma • Neuroendocrine Tumor • Oncology • Renal Disease • Solid Tumor

Management of HCV-Infection in Pediatric Patients Undergoing HCT: A Single-Center Experience (ASH 2024) - "Four patients received myeloablative conditioning consisting of TBI + etoposide and busulfan + cyclophosphamide + thiotepa for 3 and 1 patient, respectively. One patient received a reduced-intensity conditioning regimen consisting of fludarabine + cyclophosphamide...DAAs were started after discontinuation of immunosuppressive therapy, for 4/5 patients.The combination of drugs used was : glecaprevir + pibrentasvir (2 patients), sofosbuvir + velpatasvir and ledipasvir + sofosbuvir...Two patients developed CMV-reactivation and required pre-emptive therapy with valganciclovir...No data are currently available regarding the possibility of viral reactivation in patients receiving treatment before transplant. Larger studies are needed to assess the right timing of treatment based on clinical evaluations."

Clinical • Acute Lymphocytic Leukemia • Anemia • Aplastic Anemia • Bone Marrow Transplantation • Fibrosis • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Hepatology • Immunology • Infectious Disease • Leukemia • Liver Cirrhosis • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pediatrics • T Cell Non-Hodgkin Lymphoma

From Indeterminate to Invasive: A Perisplenic Nodule Unveils Metastatic Melanoma of Unknown Primary Following Brain Metastases (ACG 2025) - "This case underscores the diagnostic challenges of indeterminate visceral lesions and highlights the need for early evaluation in high-risk anatomical sites.Case Description/ A 75-year-old male with history of hepatocellular carcinoma (HCC) post resection and cirrhosis from hepatitis C (treated with ledipasvir/sofosbuvir) presented with stroke-like symptoms...This case underscores the diagnostic complexity of MUP and illustrates how a slowly enlarging, hemorrhagic perisplenic lesion—initially considered benign or indeterminate —can precede aggressive metastatic spread. It highlights the importance of early biopsy of indeterminate visceral lesions with increased size or metastases."

Metastases • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Fibrosis • Hematological Disorders • Hepatitis C • Hepatocellular Cancer • Hepatology • Immunology • Infectious Disease • Melanoma • Ophthalmology • Solid Tumor • SOX10

Hepatocellular Carcinoma With Suspected Gastric Involvement (ACG 2025) - "This case underscores the importance of considering gastric invasion in patients with large HCCs presenting with gastrointestinal symptoms.Case Description/ A 67-year-old male with history of HCV complicated by cirrhosis treated in 2016 with ledipasvir/sofosbuvir presented with progressively worsening nausea and abdominal pain for two weeks...The feculent appearing material was likely necrotic tumor contents that eroded into the stomach resulting in aspiration and the patient's death. Recent evidence has supported surgical resection as a possible next step and expedited management may be prudent to avoid complications of invasion from aggressive lesions.Figure: Triple phase CT Abdomen/Pelvis showing the large liver lesion in (a) axial and (b) coronal views."

Cardiovascular • Fibrosis • Hepatocellular Cancer • Hepatology • Immunology • Oncology • Solid Tumor

High Rate of HCV Reinfection and the Efficacy of Standard Regimens in Men Who Have Sex with Men Living with HIV. (PubMed, J Infect Chemother) - "Among the reinfection cases, two individuals without prior DAA treatment received sofosbuvir/ledipasvir for 12 weeks, while five with prior treatment received glecaprevir/pibrentasvir for 8 weeks. These findings support the need to reframe HCV as a recurrent sexually transmitted infection. To ensure sustainable control in high-risk populations, healthcare systems must evolve to allow HCV treatment to be accessible, affordable, and repeatable, as is the case with the management of other common STIs."

Journal • Hepatitis C • Human Immunodeficiency Virus • Infectious Disease • Inflammation

Efficacy and safety of sofosbuvir-based therapies for treating HCV in children: observations from a real-world setting. (PubMed, Eur J Clin Microbiol Infect Dis) - "This study confirms the excellent efficacy and good tolerability of SOF-based regimens for the treatment of hepatitis C in children aged 5 to 17 years in real-life settings, supporting the inclusion of pediatric patients in national treatment policies."

Journal • Real-world evidence • Fatigue • Fibrosis • Hepatitis C • Immunology • Infectious Disease • Inflammation • Pain • Pediatrics

Safety and efficacy of different therapeutic regimens in Egyptian adults with moderate COVID-19 infection (EVEREST): a real-world retrospective study. (PubMed, Sci Rep) - "Patients were divided into four treatment arms: standard care, sofosbuvir/daclatasvir (sovodak) plus ivermectin, sofosbuvir/ledipasvir (SOF/LED) plus hydroxychloroquine, and SOF/LED plus ivermectin...Our study reveals that most tested antiviral combinations effectively reduced hospitalization days and progressive CT scans. These regimens demonstrated efficacy in treating moderate COVID-19 to prevent disease progression and complications."

Journal • Real-world evidence • Retrospective data • Infectious Disease • Novel Coronavirus Disease

THE MAJORITY OF PATIENTS WITH HEPATITIS C NOT ACHIEVING SVR CAN BE SUCCESSFULLY RETREATED WITH FIRST-LINE REGIMENS: RESULTS: FROM A MULTIDISCIPLINARY TEAM APPROACH TO GUIDE TREATMENT DECISIONS (AASLD 2025) - "A total of 263 retreatments were given, 176 (66.9%) 1st line (103 glecaprevir/pibrentasvir, 28 sofosbuvir/velpatasvir, 20 grazoprevir/elbasvir, 18 sofosbuvir/ledipasvir, 7 others) and 87 (33.1%) 2nd line (76 sofosbuvir/velpatasvir/voxilaprevir, 11 others).98 (37.2%) had documented risk factors for reinfection. An MDT approach to treatment failure, combined with resistance testing where available, allows for the majority of patients to be retreated with 1st line DAA regimen, with comparable rates of SVR to those treated with 2nd line regimens."

Clinical • Hepatitis C • Hepatology • Infectious Disease • Inflammation

To treat or not to treat young children with hepatitis C?--real-life experience. (PubMed, Eur J Pediatr) - "This study confirms both the efficacy and tolerability of DAAs for the treatment of hepatitis C in children aged 3-6 years in a clinical setting. Qualification for treatment in this age group should be made individually on the basis of the child's ability and willingness to swallow medications."

Journal • Fibrosis • Hepatitis C • Hepatology • Immunology • Infectious Disease • Inflammation • Pain

CLINICAL OUTCOME OF HCV INFECTION IN CHILDREN: AN ANALYSIS BASED ON SIX CASES OF HCV INFECTED CHILDREN (AASLD 2025) - "Four patients received sofosbuvir and velpatasvir for 12 weeks, while the other two received ledipasvir and sofosbuvir for the same duration. This small, single-center clinical study confirms the need for early treatment of pediatric patients with HCV infection to prevent serious liver-related complications caused by long-term infection. There is an urgent need to establish an integrated pathway of screening, diagnostic, and treatment pathway for pediatric patients with HCV infection."

Clinical • Clinical data • Hepatitis C • Infectious Disease • Liver Cirrhosis • Pediatrics

DEVELOPMENT OF B-CELL LYMPHOMA AFTER TREATMENT OF HEPATITIS C WITH DIRECT-ACTING ANTIVIRAL AGENTS (AASLD 2025) - "Sofosbuvir-based HCV therapy was used in 81% of patients, including sofosbuvir-ribavirin and sofosbuvir-ledipasvir regimens...Most cases responded well to rituximab-based chemotherapy, composed of R-CHOP or similar chemotherapy regimens with complete lymphoma regression in 25% of patients, and partial lymphoma response in 41.7% of patients, and the rest of patients without fully reported responses. While direct-acting antiviral agents have provided significant benefit for patients with hepatitis C, such as prevention of liver cirrhosis and hepatocellular carcinoma, reports in recent years have described development of B-cell lymphoma after HCV clearance with direct-acting antiviral agents. Increased monitoring of patients for B-cell lymphoma following direct-acting antiviral agents treatment for HCV can allow for earlier diagnosis resulting in earlier initiation of treatment and improvement in patient outcomes."

B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Fibrosis • Gastroenterology • Hematological Malignancies • Hepatitis C • Hepatocellular Cancer • Hepatology • Immunology • Infectious Disease • Liver Cirrhosis • Lymphoma • Mantle Cell Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Solid Tumor

THE CLINICAL EPIDEMIOLOGY AND TREATMENT OF ACUTE HEPATITIS C CAUSED BY UNSAFE CLINICAL PRACTICES (AASLD 2025) - "Among the 47 patients who received DAA therapy, the regimens used were as follows: sofosbuvir/velpatasvir in 24 patients (33.3%), emitasvir/sofosbuvir in 20 patients (27.8%), ledipasvir/sofosbuvir in 2 patients (2.8%), and coblopasvir/sofosbuvir in 1 patient (1.4%). This outbreak highlights the risks of unsafe clinical practices and the importance of early detection and treatment of AHC. DAA therapy was highly effective, with all treated patients achieving SVR12. Strengthened infection control and timely intervention are crucial to preventing similar events."

Clinical • Hepatitis C • Hepatology • Infectious Disease • Inflammation

SOFOSBUVIR-BASED REGIMEN ACHIEVED HIGH VIROLOGICAL RESPONSE IN NON-GENOTYPED HCV PATIENTS FROM A GENOTYPE 3 HIGH-PREVALENCE REGION OF SOUTHWEST CHINA: A RETROSPECTIVE COHORT STUDY (SAIN-C) (AASLD 2025) - "Patients were treated with Sofosbuvir/Velpatasvir (SOF/VEL) or Ledipasvir/Sofosbuvir (LDV/SOF) ± Ribavirin(RBV) for 12 weeks. SOF-based regimen could achieve high SVR regardless of genotype testing, even in high-prevalence regions of HCV GT3 infection. We believe this simplified strategy could be considered for genotype testing unavailable areas."

Retrospective data • Fibrosis • Hepatitis C • Hepatology • Immunology • Infectious Disease • Inflammation

OUTCOMES OF DIRECT ACTING ANTIVIRAL AGENTS IN CHRONIC HEPATITIS C PATIENTS WITH PRE-EXISTING HEPATOCELLULAR CARCINOMA (AASLD 2025) - "Patients were administered various DAAs; daclatasvir+asunaprevir, sofosvubir+ribavirin, sofosbuvir+daclatasvir, ledipasvir/Sofosbuvir±ribavirin, ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin, glecaprevir/pibrentasvir, velpatasvir/Sofobuvir ± ribavirin. This study demonstrated that the DAAs achieved favorable treatment outcomes and was well tolerated in CHC patients with pre-existing HCC. HCC tumor stage, presence of viable HCC and ribavirin use was significantly associated with survival."

Clinical • Hepatitis C • Hepatocellular Cancer • Hepatology • Infectious Disease • Oncology • Solid Tumor

HOW COLLABORATIVE WORKING WILL ACHIEVE THE WHO TARGET -TO ELIMINATE HEPATITIS C VIRUS (HCV) IN CHILDREN AND YOUNG PEOPLE BY 2030 (AASLD 2025) - "Genotype 1 &3 were the most common infection; Harvoni was prescribed in 77 (48 tablets; 29 granules): Epclusa in 60 (39 tablets; 21granules); & Maviret in 18 (10 tablets; 8 granules). The UK National paediatric virtual network is safe, cost effective & popular with both families & referrers. Treatment success rate was >99% (132/133) in those who completed treatment with 100% confirmed SVR12m. It has enhanced access to anti-viral therapy for CYP who are treated closer to home, reducing travel time to specialist centres preventing long-term liver disease & spread of HCV & made a fundamental contribution to achieving NHSE target to eliminate HCV in children & adolescents ahead of the WHO 2030 target."

Clinical • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Novel Coronavirus Disease • Pediatrics

Comparative Effectiveness of Direct-Acting Antiviral Treatment for Hepatitis C Virus Infection on Depressive Symptoms in Patients With Posttraumatic Stress Disorder. (PubMed, Clin Ther) - "DAAs had very little impact on depressive symptoms for VA patients with PTSD and HCV infection."

HEOR • Journal • CNS Disorders • Depression • Hepatitis C • Infectious Disease • Inflammation • Mood Disorders • Post-traumatic Stress Disorder • Psychiatry

Viral Hepatitis Prevention and Treatment among PrEP Users – a Retrospective Long-term Cohort Study (EADV 2025) - "During PrEP follow-up, three patients were diagnosed with HCV (two genotype 1a, one genotype 4) and were treated with Ledipasvir/ Sofosbuvir or Glecaprevir/ Pibrentasvir. Routine hepatitis vaccinations within PrEP care substantially increased immunity rates: HAV immunity rates rose from 68.7% at baseline to 92.9% on their last visit. The proportion of participants with insufficient or low HBV immunity decreased from 41.0% at baseline to 22.9% at the last PrEP visit. Vaccination uptake among PrEP users was high; however, a subset of participants did not achieve sufficient immunity by their final visit."

Retrospective data • Hepatitis B • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation

Successful Use of Belatacept in Patients Who Received HCV NAT(+) Kidneys and Receiving DAAs (WTC 2025) - "All but one patient received thymoglobulin for induction, the exception of one who received basiliximab. DAA therapy included glecaprevir/pibrentasvir (MAVYRET, 45.5%), sofosbuvir/velpatasvir (EPCLUSA, 40.9%) or sofosbuvir/ledipasvir (HARVONI, 13.6%)... Belatacept is not associated with HCV treatment failure or worsened graft outcome in the studied cohort. The rate of achieving SVR 12 was 97.7% within our cohort, which is comparable to prior studies."

Clinical • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Novel Coronavirus Disease

A Case of Recurrent Graves' Disease Associated with IgG4-releated Disease (ENDO 2025) - "This is a 47-year-old male with history of recurrent Graves' disease that has reached remission twice with methimazole, Hepatitis C infection s/p 8 weeks of ledipasvir/sofosbuvir, chronic uncomplicated pancreatitis of unknown etiology. Physicians should consider the possibility of IgG4-RTD in a patient with recurrent Graves' disease as recognizing it promptly can be crucial in evaluation and management for other IgG4-RTD. Furthermore, recognition of this association might lead to development of new therapeutic approaches for example use of Rituximab in combination with anti-thyroid drugs to induce remission."

Clinical • Cardiovascular • Endocrine Disorders • Fibrosis • Grave’s Disease • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Ophthalmology • Pain • Pancreatitis • Pruritus • Thyroid Eye Disease

Long-Term Outcomes of Ledipasvir/Sofosbuvir Treatment in Hepatitis C: Viral Suppression, Hepatocellular Carcinoma, and Mortality in Mongolia. (PubMed, Viruses) - "(4) This study demonstrates that ledipasvir/sofosbuvir effectively suppresses HCV initially and maintains low viral relapse rates over the long term. However, it emphasizes the need for continued management to reduce the long-term risk of HCC and mortality, especially in patients with severe liver fibrosis or cirrhosis."

Journal • Fibrosis • Gastroenterology • Hepatitis C • Hepatocellular Cancer • Hepatology • Immunology • Infectious Disease • Liver Cirrhosis • Oncology • Solid Tumor

A global comparison of hepatitis B & C drug pricing. (PubMed, Ann Hepatol) - "HBV and HCV originator medications cost significantly more in the US compared to seven other major industrial countries. However, the introduction of HBV generic medications has lowered the cost of treatment for patients in the US. Future adoption of international reference pricing may help bridge remaining pricing disparities."

Journal • Pricing • Hepatitis B • Hepatitis C • Infectious Disease • Inflammation

HIV-HCV COINFECTION IN PREGNANCY: CAN DIRECT-ACTING ANTIVIRAL AGENTS REDUCE THE RISK OF VERTICAL TRANSMISSION? (ESPID 2025) - "ART with TDF+3TC/DTG was initiated, achieving an undetectable HIV VL and increased CD4 count. While sofosbuvir-ledipasvir is not pan-genotypic, it has the most safety and efficacy evidence in this context. This high-risk case suggests that DAA treatment during pregnancy, even in later stages, may reduce vertical transmission of HCV."

Hepatitis C • Human Immunodeficiency Virus • Infectious Disease • CD4

COMPARATIVE STUDY DEMONSTRATING THE SUPERIORITY OF DIRECT-ACTING ANTIVIRALS OVER INTERFERON PLUS RIBAVIRIN IN ALBANIAN CHILDREN WITH CHRONIC HEPATITIS C (ESPGHAN 2025) - "The second group, comprising children aged 4 to 22*years (10 boys and 2 girls), [table 2] was treated with DAAs: half received HARVONI (Ledipasvir/Sofosbuvir) for 12 weeks, and the other half received MAVYRET (Glecaprevir/Pibrentasvir) for 8 weeks. They resulted in fewer side effects and shorter treatment duration. These findings highlight the superiority of DAAs and support the WHO recommendations for treating adults, adolescents, and children as young as 3 years old."

Clinical • Head-to-Head • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Pain • Pediatrics